Dr. Goodenowe to present new multi-analyte, high-resolution/accurate-mass technology

Dr. Dayan Goodenowe, Prodrome Sciences’ Founder and CEO, will present the validation study results of Prodrome Sciences’ new multi-analyte, high-resolution/accurate-mass technology for the quantification of over 1000 acidic lipid species in human serum at the 43rd Annual Meeting of the Japanese Society for Biomedical Mass Spectrometry on September 6, 2018, in Sapporo, Japan.

Diseases such as colorectal cancer, pancreatic cancer, ovarian cancer, multiple sclerosis, Parkinson’s disease, and dementia are associated with abnormal blood levels of acidic lipids such as fatty acids (EPA, DHA), ultra-long chain fatty acids (GTA-446, PC-594), plasmalogens, phosphatidylethanolamines, and phosphatidylserines. Prodrome Sciences has developed and validated a simple, high-throughput, reproducible method for detecting and quantifying key acidic lipids in human serum.

The simplicity and robustness of Prodrome Sciences’ new technology makes comprehensive metabolomic analyses of large patient populations economically viable. Multiple databases can be easily created and analyzed, and new biomarkers can be discovered for detecting disease and disease risk.